Lung cancer is the world's most severe cancer. As a new drug for lung cancer treatment independently developed by China, Anrotinib has been approved for the back-line treatment of lung cancer. Its relevant academic achievements not only stand out in international conferences, but also is a popular topic appear in popular journals. At the beginning of 2020, the researcher analyzed patients with brain metastases in ALTER-0303 study and published the result in The Oncologist (IF=5.3). The corresponding authors of the paper are Professor He Jianxing and Associate Professor Liang Wenhua of SKLRD, and the first author is director Jiang Shunjun.

As a third-line drug, Anrotinib has achieved excellent therapeutic effects in patients with brain metastases in advanced lung cancer. There are currently ongoing clinical trials to study the value of Anrotinib in first-line treatment. Meanwhile, immunotherapy and targeted therapy are mainly adopted in present days. It is expected that Anrotinib can achieve further breakthroughs in combination with related drugs.